{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:41:22Z","timestamp":1791312082533,"version":"4.3.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hubei Urology Minimally Invasive Therapy Clinical Medical Center","award":["SCZ2023017"],"award-info":[{"award-number":["SCZ2023017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15577-3","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T23:03:37Z","timestamp":1768950217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prostate health index enhances prostate cancer management in Chinese populations: evidence from the nation\u2019s large cohort and transnational multicohort harmonization"],"prefix":"10.1186","volume":"26","author":[{"given":"Xingyu","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaogang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qidong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"2","key":"15577_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and local treatment with curative intent. Eur Urol. 2024;86(2):148\u201363.","journal-title":"Eur Urol"},{"issue":"5","key":"15577_CR2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","volume":"18","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland SJ, et al. Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol. 2021;18(5):282\u2013301.","journal-title":"Nat Rev Urol"},{"key":"15577_CR3","doi-asserted-by":"publisher","first-page":"215927","DOI":"10.1016\/j.canlet.2022.215927","volume":"550","author":"J Liu","year":"2022","unstructured":"Liu J, Dong L, Zhu Y, Dong B, Sha J, Zhu HH, et el. Prostate cancer treatment - China\u2019s perspective. Cancer Lett. 2022;550:215927.","journal-title":"Cancer Lett"},{"issue":"1","key":"15577_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JU.0000000000003491","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, et al. Early detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening. J Urol. 2023;210(1):46\u201353.","journal-title":"J Urol"},{"issue":"24","key":"15577_CR5","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: A review. JAMA. 2017;317(24):2532\u201342.","journal-title":"JAMA"},{"issue":"6","key":"15577_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.euo.2023.09.008","volume":"6","author":"A Krilaviciute","year":"2023","unstructured":"Krilaviciute A, Becker N, Lakes J, Radtke JP, Kuczyk M, Peters I, et al. Digital rectal examination is not a useful screening test for prostate cancer. Eur Urol Oncol. 2023;6(6):566\u201373.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"15577_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.eururo.2015.12.045","volume":"70","author":"ME Caram","year":"2016","unstructured":"Caram ME, Skolarus TA, Cooney KA. Limitations of prostate-specific antigen testing after a prostate cancer diagnosis. Eur Urol. 2016;70(2):209\u201310.","journal-title":"Eur Urol"},{"issue":"4","key":"15577_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/JU.0000000000003603","volume":"210","author":"K Yim","year":"2023","unstructured":"Yim K, Ma C, Carlsson S, Lilja H, Mucci L, Penney K, et el. Free PSA and clinically significant and fatal prostate cancer in the PLCO screening trial. J Urol. 2023;210(4):630\u20138.","journal-title":"J Urol"},{"key":"15577_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev.med.60.042307.110714","volume":"60","author":"DV Makarov","year":"2009","unstructured":"Makarov DV, Loeb S, Getzenberg RH, Partin AW. Biomarkers for prostate cancer. Annu Rev Med. 2009;60:139\u201351.","journal-title":"Annu Rev Med"},{"issue":"6","key":"15577_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1464-410X.2012.11329.x","volume":"112","author":"S Hori","year":"2013","unstructured":"Hori S, Blanchet JS, McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of ProPSAs in the detection and management of early prostate cancer. BJU Int. 2013;112(6):717\u201328.","journal-title":"BJU Int"},{"issue":"1","key":"15577_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/bju.13139","volume":"117","author":"M Boegemann","year":"2016","unstructured":"Boegemann M, Stephan C, Cammann H, Vincendeau S, Houlgatte A, Jung K, et el. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the prostate health index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged\u2009\u2264\u200965 years. BJU Int. 2016;117(1):72\u20139.","journal-title":"BJU Int"},{"issue":"11","key":"15577_CR12","doi-asserted-by":"publisher","first-page":"9329","DOI":"10.1007\/s00432-023-04860-6","volume":"149","author":"YM Y\u00e1\u00f1ez-Castillo","year":"2023","unstructured":"Y\u00e1\u00f1ez-Castillo YM, Melgarejo-Segura MT, Funes-Padilla C, Folgueral-Corral ME, Garc\u00eda-Larios JV, Arrabal-Polo MA, et el. Prostate health index (PHI) as an accurate prostate cancer predictor. J Cancer Res Clin Oncol. 2023;149(11):9329\u201335.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"15577_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.5858\/arpa.2021-0079-OA","volume":"146","author":"MM Garrido","year":"2022","unstructured":"Garrido MM, Marta JC, Bernardino RM, Guerra J, Fernandes F, Pereira MH, et el. The percentage of [-2]Pro-Prostate-Specific antigen and the prostate health index outperform prostate-Specific antigen and the percentage of free prostate-Specific antigen in the detection of clinically significant prostate cancer and can be used as reflex tests. Arch Pathol Lab Med. 2022;146(6):691\u2013700.","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"15577_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00345-018-2362-z","volume":"37","author":"R Mathieu","year":"2019","unstructured":"Mathieu R, Castelli C, Fardoun T, Peyronnet B, Shariat SF, Bensalah K, et el. Cost analysis of prostate cancer detection including the prostate health index (phi). World J Urol. 2019;37(3):481\u20137.","journal-title":"World J Urol"},{"issue":"9","key":"15577_CR15","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.6004\/jnccn.2014.0120","volume":"12","author":"PR Carroll","year":"2014","unstructured":"Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, et al. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12(9):1211\u20139. quiz 1219.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"15577_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1515\/cclm-2012-0410","volume":"51","author":"X Filella","year":"2013","unstructured":"Filella X, Gim\u00e9nez N. Evaluation of [-2] ProPSA and prostate health index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med. 2013;51(4):729\u201339.","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"15577_CR17","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1007\/s00345-020-03585-2","volume":"39","author":"C Stephan","year":"2021","unstructured":"Stephan C, Jung K, Lein M, Rochow H, Friedersdorff F, Maxeiner A. PHI density prospectively improves prostate cancer detection. World J Urol. 2021;39(9):3273\u20139.","journal-title":"World J Urol"},{"issue":"4","key":"15577_CR18","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.eururo.2018.10.047","volume":"75","author":"PK Chiu","year":"2019","unstructured":"Chiu PK, Ng CF, Semjonow A, Zhu Y, Vincendeau S, Houlgatte A, et al. A multicentre evaluation of the role of the prostate health index (PHI) in regions with differing prevalence of prostate cancer: adjustment of PHI reference ranges is needed for European and Asian settings. Eur Urol. 2019;75(4):558\u201361.","journal-title":"Eur Urol"},{"issue":"4","key":"15577_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.eururo.2014.10.010","volume":"67","author":"S Loeb","year":"2015","unstructured":"Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, et el. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol. 2015;67(4):619\u201326.","journal-title":"Eur Urol"},{"key":"15577_CR20","doi-asserted-by":"crossref","unstructured":"Zhou Y, Fu Q, Shao Z, Zhang K, Qi W, Geng S, et al. Nomograms combining PHI and PI-RADS in detecting prostate cancer: a multicenter prospective study. J Clin Med. 2023;12(1):339.","DOI":"10.3390\/jcm12010339"},{"issue":"6","key":"15577_CR21","doi-asserted-by":"publisher","first-page":"592","DOI":"10.4103\/aja.aja_125_18","volume":"21","author":"YS Wu","year":"2019","unstructured":"Wu YS, Fu XJ, Na R, Ye DW, Qi J, Lin XL, et al. Phi-based risk calculators performed better in the prediction of prostate cancer in the Chinese population. Asian J Androl. 2019;21(6):592\u20137.","journal-title":"Asian J Androl"},{"key":"15577_CR22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"15577_CR23","doi-asserted-by":"publisher","first-page":"k3519","DOI":"10.1136\/bmj.k3519","volume":"362","author":"D Ilic","year":"2018","unstructured":"Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et el. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519.","journal-title":"BMJ"},{"issue":"9959","key":"15577_CR24","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","volume":"384","author":"FH Schr\u00f6der","year":"2014","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027\u201335.","journal-title":"Lancet"},{"issue":"6","key":"15577_CR25","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.eururo.2013.01.011","volume":"63","author":"M Lazzeri","year":"2013","unstructured":"Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2\u201310 ng\/ml: a multicentric European study. Eur Urol. 2013;63(6):986\u201394.","journal-title":"Eur Urol"},{"issue":"4","key":"15577_CR26","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41391-021-00444-y","volume":"25","author":"AQ Liu","year":"2022","unstructured":"Liu AQ, Remmers S, Lau SY, Yip SY, Leung CH, Mak CW, et al. Initial prostate health index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study. Prostate Cancer Prostatic Dis. 2022;25(4):684\u20139.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"15577_CR27","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.eururo.2013.02.004","volume":"63","author":"S Loeb","year":"2013","unstructured":"Loeb S. Prostate health index (PHI): golden bullet or just another prostate cancer marker? Eur Urol. 2013;63(6):995\u20136. discussion 996\u2013997.","journal-title":"Eur Urol"},{"issue":"8","key":"15577_CR28","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1515\/cclm-2022-0354","volume":"60","author":"L Agnello","year":"2022","unstructured":"Agnello L, Vidali M, Giglio RV, Gambino CM, Ciaccio AM, Lo Sasso B, et al. Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med. 2022;60(8):1261\u201377.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"15577_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41585-019-0212-4","volume":"17","author":"A Stabile","year":"2020","unstructured":"Stabile A, Giganti F, Rosenkrantz AB, Taneja SS, Villeirs G, Gill IS, et el. Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nat Rev Urol. 2020;17(1):41\u201361.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"15577_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13244-024-01699-4","volume":"15","author":"E Guo","year":"2024","unstructured":"Guo E, Xu L, Zhang D, Zhang J, Zhang X, Bai X, et al. Diagnostic performance of MRI in detecting prostate cancer in patients with prostate-specific antigen levels of 4\u201310 ng\/mL: a systematic review and meta-analysis. Insights Imaging. 2024;15(1):147.","journal-title":"Insights Imaging"},{"issue":"23","key":"15577_CR31","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","volume":"387","author":"J Hugosson","year":"2022","unstructured":"Hugosson J, M\u00e5nsson M, Wallstr\u00f6m J, Axcrona U, Carlsson SV, Egevad L, et al. Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N Engl J Med. 2022;387(23):2126\u201337.","journal-title":"N Engl J Med"},{"issue":"9","key":"15577_CR32","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41585-022-00638-6","volume":"19","author":"H Van Poppel","year":"2022","unstructured":"Van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat Rev Urol. 2022;19(9):562\u201372.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"15577_CR33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.eururo.2021.11.019","volume":"82","author":"VH Meissner","year":"2022","unstructured":"Meissner VH, Rauscher I, Schwamborn K, Neumann J, Miller G, Weber W, et el. Radical prostatectomy without prior biopsy following multiparametric magnetic resonance imaging and Prostate-specific membrane antigen positron emission tomography. Eur Urol. 2022;82(2):156\u201360.","journal-title":"Eur Urol"},{"issue":"2","key":"15577_CR34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/JU.0000000000004025","volume":"212","author":"S Niu","year":"2024","unstructured":"Niu S, Ding X, Liu B, Ao L, Wang H, Chen W, et al. Radical prostatectomy without prior biopsy in selected patients evaluated by (18)F-Labeled Prostate-Specific membrane Antigen-Ligand positron emission tomography\/Computed tomography and multiparameter magnetic resonance imaging: A Single-Center, Prospective, Single-Arm trial. J Urol. 2024;212(2):280\u20139.","journal-title":"J Urol"},{"issue":"6","key":"15577_CR35","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.21037\/tau-20-489","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhang B, Xia S, Li T, Liu R. Prostate biopsy free system for laparoscopic radical prostatectomy in a pituitary dwarfism: a case report. Translational Androl Urol. 2020;9(6):2831\u20135.","journal-title":"Translational Androl Urol"},{"issue":"2","key":"15577_CR36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4111\/kju.2012.53.2.82","volume":"53","author":"JY Jang","year":"2012","unstructured":"Jang JY, Kim YS. Is prostate biopsy essential to diagnose prostate cancer in the older patient with extremely high prostate-specific antigen? Korean J Urol. 2012;53(2):82\u20136.","journal-title":"Korean J Urol"},{"key":"15577_CR37","doi-asserted-by":"crossref","unstructured":"Zhong X, Ming Z, He H, Xiong Y, Wang S, Xia Q. A Highly Sensitive Methylation Assay for Prostate Cancer Diagnosis. The world journal of men\u2019s health 2025.","DOI":"10.5534\/wjmh.240182"},{"issue":"1","key":"15577_CR38","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","volume":"15","author":"NM Fonseca","year":"2024","unstructured":"Fonseca NM, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha AJ, Kollmannsberger C, Kwan EM, Parekh K, Sch\u00f6nlau E, et al. Prediction of plasma ctdna fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat Commun. 2024;15(1):1828.","journal-title":"Nat Commun"},{"issue":"10","key":"15577_CR39","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1007\/s00432-022-04213-9","volume":"148","author":"M de N\u00f3brega","year":"2022","unstructured":"de N\u00f3brega M, Dos Reis MB, Pereira \u00c9R, de Souza MF, de Syllos C\u00f3lus IM. The potential of cell-free and Exosomal MicroRNAs as biomarkers in liquid biopsy in patients with prostate cancer. J Cancer Res Clin Oncol. 2022;148(10):2893\u2013910.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15577-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15577-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15577-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:10:30Z","timestamp":1771434630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15577-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15577"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15577-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Informed consent and approval were obtained from all the patients and the Ethics Committee of Tongji Hospital (TJ-IRB202407023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}